Autophagy inducer rapamycin treatment reduces IFN-I-mediated Inflammation and improves anti-HIV-1 T cell response in vivo

By sjmartinez • December 13, 2022

Mu W, Rezek V, Martin H, Carrillo MA, Tomer S, Hamid P, Lizarraga MA, Tibbe TD, Yang OO, Jamieson BD, Kitchen SG, Zhen A. Autophagy inducer rapamycin treatment reduces IFN-I-mediated Inflammation and improves anti-HIV-1 T cell response in vivo. JCI Insight. 2022 Nov 22;7(22):e159136. doi: 10.1172/jci.insight.159136. PMID: 36509289.

Tags: AIDS/HIV, Cellular immune response, Hematology/Oncology, Infectious Diseases, Inflammation, innate immunity, Publications

Real-world clinical outcomes of Trastuzumab Deruxtecan in HER2-expressing ovarian and endometrial Cancer

Silverstein J, Alomaja O, Chatram D, Hajiabbasi M, Shachar E, Tseng CH, Thaker S, Bardia A, Karlan B, Hendrickson AW, Konecny GE. Real-world clinical outcomes[...]

Fixed-duration epcoritamab plus R-CHOP in newly diagnosed LBCL with IPI score 3-5: results from the EPCORE NHL-2 trial

Falchi L, Offner F, de Vos S, Brody JD, Morillo D, Linton K, Snauwaert S, Roost Clausen M, Karimi YH, Thieblemont C, Vitolo U, Leslie[...]

Danvatirsen plus pembrolizumab versus pembrolizumab for recurrent and/or metastatic head and neck squamous cell carcinoma (PEMDA-HN): a randomized, phase 2 trial

Saba NF, Posner M, Harrington K, Neupane P, Rezaee R, Nenclares P, Jimeno A, Denker AE, MacIntyre S, Makris L, Wong D. Danvatirsen plus pembrolizumab[...]